Detection of circulating plasma tumour mutations in early stage triple negative breast cancer as an adjunct to pathological complete response assessment.
Zaikova, E.; Cheng, B. Y.; Cerda, V.; Kong, E.; Lai, D.; Lum, A.; Bates, C.; den Brok, W.; Kono, T.; Bourque, S.; Chan, A.; Feng, X.; Fenton, D.; Gurjal, A.; Levasseur, N.; Lohrisch, C.; Roberts, S.; Shenkier, T.; Simmons, C.; Taylor, S.; Villa, D.; Miller, R.; Aguirre-Hernandez, R.; Aparicio, S.; Gelmon, K.
Show abstract
Circulating tumour DNA (ctDNA) detection in liquid biopsy is an emerging alternative to tissue biopsy, but its utility in treatment response monitoring and prognosis in triple negative breast cancer (TNBC) is not yet well understood. In this study, we determined the presence of ctDNA detectable actionable mutations with a clinically validated hotspot treatment indication panel in early stage TNBC patients, without local recurrence or metastatic disease at the time of evaluation. Sequencing of plasma DNA and validation of variants from 130 TNBC patients collected within 7 months of primary treatment completion revealed that 7.7% had detectable residual disease with a hotspot panel. Among neoadjuvant treated patients, we observed a trend where patients with incomplete pathologic response and positive ctDNA within 7 months of treatment completion were at much higher risk of reduced progression free survival. We propose that a high risk subset of early TNBC patients treated in NAT protocols may be identifiable by combining tissue response and sensitive ctDNA detection.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cell-free urine- and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle invasive bladder cancer 96%
- Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up 95%
- Clinicogenomic characterization of inflammatory breast cancer 94%
Similar papers in this journal
- Clonal hematopoiesis is associated with risk of severe Covid-19 96%
- Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes 96%
- Multiplexed RNA-FISH-guided Laser Capture Microdissection RNA Sequencing Improves Breast Cancer Molecular Subtyping, Prognostic Classification, and Predicts Response to Antibody Drug Conjugates 96%
Similar papers in this journal
- RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer 96%
- The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ 94%
- The clinical and molecular significance associated with STING signaling in estrogen receptor-positive early breast cancer 94%
Similar papers in this journal
- Germline rare deleterious variant load alters cancer risk, age of onset and tumor characteristics 94%
- Development and validation of a gene expression score to account for tumour purity and improve prognostication in breast cancer 94%
- Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers 93%
Similar papers in this journal
- Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma 93%
- Germline testing data validate inferences of mutational status for variants detected from tumor-only sequencing 93%
- Mutational footprint of platinum chemotherapy in a secondary thyroid cancer 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.